Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 4
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
KRAS G12D
NSCLC · Monoclonal Antibody
KRAS G12D is flagged as trial selection rising because public trials show inclusion required evidence in 4 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 6
Common snippets: MET exon 14 skipping | EGFR Exon 19 deletion | KRAS G12C
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT02648724 | https://clinicaltrials.gov/study/NCT04310007 | https://clinicaltrials.gov/study/NCT07416058 | https://clinicaltrials.gov/study/NCT06868836